Ezetimibe: a novel option for lowering cholesterol (Q44804875)

6 December 2017

title

Ezetimibe: a novel option for lowering cholesterol (English)

1 reference

6 December 2017

Michael H Davidson

1

1 reference

6 December 2017

publication date

1 May 2003

1 reference

Expert Review of Cardiovascular Therapy

6 December 2017

published in

1 reference

6 December 2017

volume

1

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

11-21

1 reference

Cholesterol and mortality. 30 years of follow-up from the Framingham study

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Antihyperlipidaemic agents. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Dietary cholesterol absorption; more than just bile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

The LDL receptor locus in familial hypercholesterolemia: Multiple mutations disrupt transport and processing of a membrane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

Serum plant sterols as a potential risk factor for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.11

21 January 2018

Identifiers

DOI

10.1586/14779072.1.1.11

1 reference

6 December 2017

1 reference